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Background—Prominent features of myocardial remodeling in heart failure with preserved ejection fraction (HFPEF)
are high cardiomyocyte resting tension (Fpassive) and cardiomyocyte hypertrophy. In experimental models, both
reacted favorably to raised protein kinase G (PKG) activity. The present study assessed myocardial PKG activity,
its downstream effects on cardiomyocyte Fpassive and cardiomyocyte diameter, and its upstream control by cyclic
guanosine monophosphate (cGMP), nitrosative/oxidative stress, and brain natriuretic peptide (BNP). To discern
altered control of myocardial remodeling by PKG, HFPEF was compared with aortic stenosis and HF with reduced
EF (HFREF).
Methods and Results—Patients with HFPEF (n36), AS (n67), and HFREF (n43) were free of coronary artery
disease. More HFPEF patients were obese (P0.05) or had diabetes mellitus (P0.05). Left ventricular myocardial
biopsies were procured transvascularly in HFPEF and HFREF and perioperatively in aortic stenosis. Fpassive was
measured in cardiomyocytes before and after PKG administration. Myocardial homogenates were used for
assessment of PKG activity, cGMP concentration, proBNP-108 expression, and nitrotyrosine expression, a
measure of nitrosative/oxidative stress. Additional quantitative immunohistochemical analysis was performed for
PKG activity and nitrotyrosine expression. Lower PKG activity in HFPEF than in aortic stenosis (P0.01) or
HFREF (P0.001) was associated with higher cardiomyocyte Fpassive (P0.001) and related to lower cGMP
concentration (P0.001) and higher nitrosative/oxidative stress (P0.05). Higher Fpassive in HFPEF was corrected
by in vitro PKG administration.
Conclusions—Low myocardial PKG activity in HFPEF was associated with raised cardiomyocyte Fpassive and was related
to increased myocardial nitrosative/oxidative stress. The latter was probably induced by the high prevalence in
HFPEF of metabolic comorbidities. Correction of myocardial PKG activity could be a target for specific HFPEF
treatment. (Circulation. 2012;126:830-839.)
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Despite modern heart failure (HF) therapy, prognosis ofheart failure with preserved ejection fraction (HFPEF)
has not improved over the last decades.1 This epidemiological
finding confirmed the neutral result of numerous large out-
come trials testing modern pharmacotherapy in HFPEF.2 The
neutral outcome of these trials has been variably ascribed to
trial design and to failure to address features of myocardial
dysfunction and remodeling prominently present in HFPEF.3
Prominent clinical features of myocardial dysfunction in
HFPEF are slow relaxation and high diastolic stiffness.4 High
diastolic stiffness is also present in muscle strips5 and single
cardiomyocytes6,7 isolated from left ventricular (LV) myocar-
dium of HFPEF patients. Slow relaxation and high diastolic
stiffness have both been shown to react favorably to raised
protein kinase G (PKG) activity after in vivo administration
of sildenafil, which raises myocardial PKG activity through
inhibited breakdown of cyclic guanosine monophosphate
(cGMP) by phosphodiesterase 5A (PDE5A). Sildenafil re-
stored LV relaxation kinetics in mice exposed to transverse
aortic constriction (TAC)8 and reduced diastolic LV stiffness
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in an old hypertensive dog model,9 in patients with HF and
reduced EF (HFREF)10 and in HFPEF patients with pulmo-
nary hypertension.11 Administration of sildenafil to old hy-
pertensive dogs lowered diastolic LV stiffness through re-
stored phosphorylation of the N2B segment of titin,9 which
was recently shown to be hypophosphorylated in HF pa-
tients12 and to have PKG phosphorylation sites.13 Prominent
features of myocardial remodeling in HFPEF are cardiomyo-
cyte hypertrophy and interstitial fibrosis.7 Modulation of the
soluble guanylate cyclase (sGC)-PKG-PDE5A axis also af-
fected myocardial remodeling with less cardiomyocyte hy-
pertrophy and interstitial fibrosis in TAC mice exposed to
sildenafil.8
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Because of these promising experimental and clinical
effects of sildenafil on myocardial dysfunction and remodel-
ing in HFPEF and because of the ongoing large outcome trial
testing sildenafil in HFPEF (RELAX study: http://www.
clinicaltrials.gov; unique identifier: NCT00763867), the pres-
ent study measured PKG activity, upstream control of PKG
activity, and downstream effects of PKG activity in LV myo-
cardial biopsies of HFPEF patients. To discern altered control by
PKG of the myocardial remodeling process in HFPEF, measure-
ments were compared with measurements obtained from LV
myocardium remodeled concentrically by severe aortic stenosis
(AS) or eccentrically by nonischemic HFREF.
Methods
Patients
HF patients had been hospitalized for worsening HF and referred for
cardiac catheterization and transvascular LV endomyocardial biopsy
procurement because of suspicion of infiltrative or inflammatory
myocardial disease. Patients were included if coronary angiography
ruled out significant epicardial coronary artery stenosis (50%) and
if histological examination of the biopsy showed no evidence of
infiltrative or inflammatory myocardial disease. The HF patient
study cohort consisted of 79 patients, of whom 36 were classified as
HFPEF and 43 as HFREF. Patients were diagnosed as HFPEF if they
had LV ejection fraction (LVEF) 50%, LV end-diastolic volume
index 97 mL/m2, and LV end-diastolic pressure 16 mm Hg.14
Patients were classified as HFREF if LVEF was 45%. No HF
patient had cardiac resynchronization therapy or a LV assist device.
The AS group consisted of 67 patients with symptomatic AS (mean
aortic valve area 0.530.04 cm2) and without significant coronary
disease. In this group, LV biopsy material consisted of LV endo-
myocardial tissue resected from the LV outflow tract (Morrow
procedure) because of concomitant LV outflow tract narrowing.
Hemodynamic data of HFREF, HFPEF, and AS patients are listed in
the Table. LV peak-systolic pressure, LVEDP, LV end-diastolic
volume index, and LVEF were derived from biplane LV angiograms.
Diastolic posterior wall thickness and LV mass index were derived
from 2-dimensional echocardiograms. The local ethics committee
approved the study protocol. Written informed consent was obtained
from all patients, and there were no complications related to
procedure or biopsy procurement.
Histomorphometric Myocardial Analysis
Histomorphometric analysis of biopsy samples was performed on
hematoxylin-and-eosin-stained 4-m-thick sections of tissue placed
in 5% formalin. Images of these sections were acquired with a
projection microscope (200) and subsequently analyzed with
Slidebook 4.0 software (3I, Denver, CO) to determine cardiomyo-
cyte diameter (m, 17.11.5 cardiomyocytes measured per patient)
and reactive interstitial fibrosis, expressed as collagen volume
fraction (%, 4.10.3 representative fields per patient).7,15
Force Measurements in Isolated Cardiomyocytes
Force measurements were performed in single, mechanically isolated
cardiomyocytes as described previously (2.60.1 cardiomyocytes
per patient).6,7,12 Biopsy samples (5 mg wet weight) were defrosted
in relaxing solution, mechanically disrupted, and incubated for 5
minutes in relaxing solution supplemented with 0.2% Triton X-100
to remove all membrane structures. Single cardiomyocytes were
stretched to a sarcomere length of 2.2 m to measure passive force
(Fpassive). Fpassive measurements were repeated after 40 minutes of
incubation in relaxing solution containing PKG1 (0.1 U/mL;
Sigma, St. Louis, MO, batch034K1336) and cGMP (10 mol/L,
Sigma).
Myocardial PKG Activity
Myocardial PKG activity was assessed in homogenized tissue
samples. Tissues samples were homogenized in 25 mmol/L Tris (pH
7.4), 1 mmol/L EDTA, 2 mmol/L EGTA, 5 mmol/L dithiothreitol,
0.05% Triton X-100, and protease inhibitor cocktail (Sigma-Aldrich)
and centrifuged for 5 minutes. Supernatants containing equal
amounts of total protein were analyzed for PKG activity. The
reaction mixture contained (at final concentration): 40 mmol/L
Tris-HCl (pH 7.4), 20 mmol/L magnesium acetate, 0.2 mmol/L
[32P]ATP (500–1000 cpm pmol–1; Amersham Pharmacia Biotech,
Amersham, UK), 113 mg/mL heptapeptide (RKRSRAE), 3 mol/L
cGMP (Promega, Madison, WI), and a highly specific inhibitor of
cyclic adenosine monophosphate-dependent protein kinase (5–24,
Calbiochem, Schiphol-Rijk, the Netherlands). The reaction mixtures
were incubated at 30°C for 10 min, followed by termination of the
reaction by spotting 70 L of the reaction mix onto Whatman P-81
filters, which were then soaked with 75 mmol/L H3PO4 for 5 min
and washed 3 times with 75 mmol/L H3PO4 to remove any unbound
[32P]ATP. Filters were rinsed with 100% ethanol and air dried before
quantification. For quantification of PKG activity, counts were taken
in a Wallac 1409 Liquid Scintillation Counter using universal
scintillation cocktail (ICN). Specific activity of PKG was expressed
as pmol of 32P incorporated into the substrate (pmol/min/mg protein).
Immunohistochemical analysis was performed on formalin-fixed
tissue sections. Myocardial PKG activity was measured immunohis-
tochemically by ratio of vasodilatory-stimulated phosphoprotein
(VASP) phosphorylated at Ser239 (pVASP) to total VASP (pVASP/
VASP ratio).16 Biopsy samples were stained with mouse monoclonal
anti Ser239 pVASP antibody (16C2; #676602,Calbiochem) for de-
tection of pVASP, and with mouse monoclonal anti-VASP antibody
(A-11. 1:50; sc-46668, Santa Cruz Biotechnology, Inc, Santa Cruz,
CA) for detection of VASP. All incubations were done for 1 hour at
room temperature. Samples were then incubated with antimouse/
rabbit Envision (undiluted; K5007; Dako Cytomation) for 30 min-
utes at room temperature. Staining was visualized using 3,3-
diaminobenzidine (DAB, 0,1 mg/mL, 0.02% H2O2). Sections were
then counterstained with hematoxylin, dehydrated, and covered.
With each staining a PBS control or an irrelevant antibody was used.
All these controls yielded negative results. pVASP and VASP levels
were calculated, using Slidebook 4.0 software, as respective myo-
cardial positive staining areas relative to total myocardial area
(4.80.4 representative fields per patient).
Myocardial cGMP Concentration
Myocardial cGMP was determined in homogenates by use of
parameter cGMP assay immunoassay kit (R&D Systems, Minneap-
olis, MN), in which cGMP present in the homogenate competes with
fixed amount of horseradish peroxidase–labeled cGMP for sites on a
rabbit polyclonal antibody. The homogenates were diluted in cell
lysis buffer, and 100 L of 0.025 g/L protein aliquots were
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assayed according to manufacturer’s instructions. Results of dupli-
cate determinations were averaged and expressed as pmol/mL.
Myocardial Nitrotyrosine, proBNP-108, sGC, and
PDE5A Expression
Gel electrophoresis and Western blot were performed to analyze
expression of nitrotyrosine protein (dilution 1:1000, Upstate, Bil-
lerica, MA) and proBNP-108 (dilution 1:500, NOVUS Biologicals,
Littleton, CO). Biopsies were resuspended in 1 mL cold 10%
trichloroacetic acid solution (dissolved in acetone containing 0.1%
[wt/vol] dithiothreitol). Trichloroacetic acid solution–treated tissue
pellets were homogenized in sample buffer containing 15% glycerol,
62.5 mmol/L Tris (pH 6.8), 1% (wt/vol) SDS, and 2% (wt/vol)
dithiothreitol. Samples (dry weight) were applied in a concentration
that was within the linear range of detection. After one-dimensional
separation, proteins were transferred to Hybond ECL nitrocellulose
membranes. Blots were preincubated with 0.5% milk powder or 3%
bovine serum albumin in TTBS (Tween Tris-buffered saline;
10 mmol/L Tris-HCl pH 7.6, 75 mmol/L NaCl, 0.1% Tween) for 1
hour at room temperature. The blots were incubated overnight at 4°C
with primary rabbit polyclonal antibodies against nitrotyrosine (di-
lution 1:500, NOVUS Biologicals) and proBNP-108. After washing
with TTBS, primary antibody binding was visualized using a
secondary horseradish peroxidase-labeled, goat-antirabbit or goat-
antimouse (dilution 1:1000; DakoCytomation), and enhanced chemi-
luminescence (ECL Western blotting detection, Amersham Biosci-
ences). All signals were normalized to actin (dilution 1:1000; clone
KJ43A; Sigma) stained on the same blots. Staining was visualized
using the LAS-3000 Image Reader (460 nm/605 nm Ex/Em; 2-s
illumination), and signals were analyzed with AIDA software.
Myocardial nitrotyrosine content was also assessed immunohisto-
chemically with biopsy samples stained with mouse monoclonal
antinitrotyrosine antibody (HM.11,1:50,ab7048, Abcam). Myocar-
dial nitrotyrosine levels were calculated as respective myocardial
staining areas relative to total myocardial area (representative fields
per patient: 9.71.2).
For detection of myocardial sGC and PDE5A levels, biopsy
samples were stained with rabbit polyclonal guanylate cyclase beta1
antibody (1:100, ab24824, Abcam) and rabbit polyclonal PDE5A
antibody (1:10, ab14672, Abcam), respectively. Myocardial sGC and
PDE5A levels were calculated as respective myocardial positive
staining areas relative to total myocardial area (representative fields
per patient: sGC 6.91.0; PDE5A 22.73.5). For immunohisto-
chemical assessment of nitrotyrosine content and sGC or PDE5A
expression, incubation procedures, secondary antibodies, and visu-
alization techniques were similar to the aforementioned immunohis-
tochemical assessment of pVASP or VASP.
Table. Clinical, Hemodynamic, and Echocardiographic Characteristics
HFREF
(n43)
HFPEF
(n36)
AS
(n67)
P Value
(HFPEF vs HFREF)
P Value
(HFPEF vs AS)
Age, y 60.02.1 63.82.0 65.31.6 0.21 0.57
Male, % 70 56 47 0.24 0.53
Hypertension, % 16 78 58 0.0001 0.07
DM % 30 47 26 0.16 0.047
BMI, kg/m2 27.50.8 30.41.0 28.10.6 0.023 0.031
Body surface area, (BSA, m2) 1.910.03 1.940.04 1.770.03 0.57 0.002
Atrial fibrillation, % 33 14 2 0.067 0.028
Medication
ACE-I/ARB, % 81 81 43 1.00 0.0001
-blocker, % 63 53 61 0.49 0.52
Diuretic, % 72 78 54 0.61 0.028
Aldosterone receptor antagonist, % 74 47 7 0.020 0.0001
Digoxin, % 33 14 2 0.067 0.028
Statin, % 21 42 46 0.054 0.83
Metformin, % 14 17 3 0.76 0.049
Bronchodilators, % 19 17 9 1.00 0.34
Hemodynamics
HR, beats/min 824 752.0 742.0 0.073 0.71
LVPSP, mm Hg 1203 1666 2234 0.0001 0.0001
LVEDP, mm Hg 22.31.4 25.11.1 22.81.4 0.12 0.21
LVEDVI, ml/m2 1275 803 552 0.0001 0.0001
LVEF, % 29.41.5 58.42.1 64.01.2 0.0001 0.016
Echocardiography
PWTd, mm 9.560.32 11.00.26 11.00.23 0.0011 0.93
LVMI/LVEDVI 1.030.06 1.740.07 2.550.17 0.0001 0.0001
HFREF indicates heart failure with reduced ejection fraction; HFPEF, heart failure with preserved ejection fraction; AS, aortic
stenosis; DM, diabetes mellitus; BMI, body mass index; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
blocker; HR, heart rate; LVPSP, left ventricular peak-systolic pressure; LVEDP, left ventricular end-diastolic pressure; LVEDVI, left
ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; PWTd, diastolic posterior wall thickness; and LVMI, left
ventricular mass index.
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Statistical Analysis
Values are given as meanSEM. A 2-tailed test with a P value
0.05 was considered significant. Single comparisons were assessed
by an unpaired Student t test. Bonferroni-adjusted t tests were used
subsequent for multiple comparisons after ANOVA. If Levene test
revealed unequal variances, unequal-variance t test or Welch’s
ANOVA was used. The significance for categorical variables was
determined by the Fisher’s exact test. Statistical analysis was
performed with SPSS (Version 15.0; SPSS Inc, Chicago, IL).
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Clinical, Hemodynamic, and
Echocardiographic Characteristics
Hypertension was more prevalent in HFPEF than in HFREF,
and diabetes mellitus (DM) was more prevalent in HFPEF
than in AS (Table). HFPEF patients had a higher body mass
index than both HFREF and AS patients. In both HF groups,
there was more frequent use of angiotensin converting en-
zyme inhibitor or angiotensin II receptor blockers, diuretics,
and digoxin. Aldosterone receptor antagonists were used
more frequently in HFREF than in HFPEF and AS, whereas
statins were used less frequently in HFREF than in HFPEF
and AS. There was a progressive rise of LV peak-systolic
pressure, LVEF, and LV mass index/LV end-diastolic vol-
ume index from HFREF to HFPEF and to AS, and a
progressive fall of LV end-diastolic volume index from
HFREF to HFPEF and to AS. LVEDP was similar in all 3
conditions. Diastolic posterior wall thickness was equally
elevated in HFPEF and AS compared with HFREF.
Force Measurements in Isolated Cardiomyocytes
Cardiomyocyte Fpassive was higher in HFPEF (7.60.4 kN/m2
n18) than in AS (3.40.2 kN/m2; n39; P0.001) and in
HFREF (5.10.2 kN/m2; n22; P0.001; Figure 1A and
1B). When patients were subdivided in accordance to absence
or presence of DM (Table) (DM, DM), Fpassive was higher
in HFPEF-DM than in AS-DM or HFREF-DM and also
higher in HFPEF-DM than in AS-DM or HFREF-DM
(Figure I in the online-only Data Supplement). After admin-
istration of PKG, Fpassive fell significantly in HFREF, HFPEF,
and AS (Figure 1B). The fall in Fpassive was significantly
larger in HFPEF than in AS or HFREF (Figure 1C). Fpassive of
normal human cardiomyocytes is 2.80.1 kN/m2 and re-
mains unchanged after PKG administration (2.60.1
kN/m2).6,12
Myocardial PKG Activity and
cGMP Concentration
PKG activity in myocardial tissue homogenates was signifi-
cantly lower in HFPEF (5.110.62 pmol/min/mg; n12)
than in both AS (9.180.64 pmol/min/mg; n12; P0.01)
and HFREF (11.512.0 pmol/min/mg; n12; P0.001;
Figure 2A). In subsets of DM and DM patients, PKG
activity was lower in HFPEF-DM than in AS-DM or
HFREF-DM and also lower in HFPEF-DM than in
HFREF-DM (Figure I in the online-only data supplement).
Immunohistochemical determination of myocardial PKG ac-
tivity by pVASP/VASP ratio provided confirmatory evidence
as it was also significantly lower in HFPEF (0.700.03;
n9) than in both AS (0.840.02; n18; P0.001) and
HFREF (0.850.03; n14; P0.001; Figure 2B and 2C).
Myocardial cGMP concentration was significantly lower in
HFPEF (11.00.7 pmol/mL; n18) than in both AS
(98.913.9 pmol/mL; n20; P0.001) and HFREF
(168.823.6 pmol/mL; n22; P0.001; Figure 3). In sub-
sets of DM and DM patients, cGMP concentration was
lower in HFPEF-DM than in AS-DM or HFREF-DM
Figure 1. A, Single cardiomyocyte
mounted between force transducer and
piezoelectric motor. B, Higher cardiomyo-
cyte Fpassive in HFPEF than in HFREF or
AS with a significant fall in Fpassive after
PKG administration in all 3 conditions. C,
Larger fall in cardiomyocyte Fpassive after
PKG administration in HFPEF than in
HFREF or AS. HFPEF indicates heart fail-
ure with preserved ejection fraction;
HFREF, heart failure with reduced ejection
fraction; AS, aortic stenosis; and PKG,
protein kinase G.
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and also lower in HFPEF-DM than in AS-DM or HFREF-
DM (Figure I in the online-only data supplement).
Myocardial Nitrotyrosine, proBNP-108, sGC, and
PDE5A Expression
Unequal nitrotyrosylation of proteins in HFPEF (n12), AS
(n16), and HFREF (n18) myocardium was investigated
for proteins ranging from 240 kDa to 10 kDa. Strong
differential nitrotyrosylation (HFPEF: 0.340.08 a.u.; AS:
0.050.02 a.u., P0.01; HFREF:0.100.03 a.u., P0.01)
was observed in a 66-kDa protein (Figure 4A) and weak
differential nitrotyrosylation in 210-kDa and 20-kDa proteins.
None of these proteins was identified. Immunohistochemical
determination of myocardial nitrotyrosine content was also
significantly higher in HFPEF (3.940.24%) than in both
AS (3.260.13%; P0.05) and HFREF (2.640.24%;
P0.001; Figure 4B and 4C). When HFPEF, AS, and
HFREF patients were pooled, myocardial nitrotyrosine con-
tent related to cardiomyocyte Fpassive (r0.68; P0.016).
Myocardial proBNP-108 expression was significantly lower
in HFPEF (0.220.07 a.u.; n12) than in HFREF
(0.760.26 a.u.; n16; P0.05) and similar in HFPEF and
AS (0.180.05 a.u.; n16; Figure 5). Immunohistochemical
analysis demonstrated similar myocardial expression levels
of sGC (HFPEF: 3.670.38%, n4; AS: 3.370.14%,
n6; HFREF 3.930.34%, n4) and PDE5A (HFPEF:
20.41.0%, n6; AS: 21.40.8%, n7; HFREF 23.3
1.3%, n5) in all groups.
Histomorphometric Myocardial Analysis
Cardiomyocyte diameter was similarly elevated in HFPEF
(28.10.2 m; n12) and AS (28.70.3 m; n18), but
Figure 2. A, Lower PKG activity in myocardial tissue homogenates in HFPEF than in HFREF or in AS. B, Representative immunohisto-
chemical images stained for pVASP and VASP in HFREF, HFPEF, and AS. C, Lower myocardial PKG activity assessed by immunohis-
tochemical pVASP/VASP ratio in HFPEF than in HFREF or in AS. HFPEF indicates heart failure with preserved ejection fraction; HFREF,
heart failure with reduced ejection fraction; pVASP, phosphorylated at Ser239; VASP, vasodilatory-stimulated phosphoprotein; PKG, pro-
tein kinase G; and AS, aortic stenosis.
Figure 3. Lower myocardial cGMP concentration in HFPEF than
in HFREF or in AS. cGMP indicates cyclic guanosine mono-
phosphate; HFPEF, heart failure with preserved ejection fraction;
HFREF, heart failure with reduced ejection fraction; and AS, aor-
tic stenosis.
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lower in HFREF (24.70.3 m; n21; P0.001 versus
HFPEF). Collagen volume fraction was comparable in
HFPEF (11.30.3%; n31) and HFREF (12.20.4%;
n36) but higher in AS (14.11.1%; n33; P0.002 versus
HFPEF).
Discussion
The present study reveals reduced PKG activity and lower
cGMP concentration in concentrically remodeled LV myo-
cardium of HFPEF patients than in concentrically remodeled
myocardium of AS patients and than in eccentrically remod-
eled LV myocardium of HFREF patients. Reduced PKG
activity and lower myocardial cGMP concentration in HFPEF
did not result from altered myocardial sGC or PDE5A
expression, which was similar in all groups nor from unequal
natriuretic peptide (NP) expression, which was comparable in
HFPEF and AS. The downregulated cGMP-PKG signaling in
HFPEF was more likely related to low myocardial nitric
oxide (NO) bioavailability because of high nitrosative/oxida-
tive stress. High nitrosative/oxidative stress in HFPEF was
inferred in the present study from the higher myocardial
nitrotyrosine content in HFPEF than in both HFREF and AS.
Lower PKG activity affected myocardial dysfunction in
HFPEF as evident from the higher cardiomyocyte Fpassive in
HFPEF and the correction of this higher Fpassive by in vitro
administration of PKG.
Myocardial PKG Signaling in HFPEF
The present study is the first to comprehensively compare
myocardial PKG activity, its downstream effects on cardio-
myocyte stiffness and hypertrophy, and its upstream control
by cGMP, sGC, PDE5A, nitrosative/oxidative stress, and
proBNP-108 in different forms of human cardiac remodeling,
consisting respectively of HFPEF- and AS-associated con-
centric remodeling and of HFREF-associated eccentric re-
modeling. Upregulated PDE5A expression was previously
observed in remodeled human myocardial tissue procured
at cardiac surgery from hypertrophied right ventricles of
congenital cardiac malformations17 or at cardiac transplan-
tation from explanted dilated or ischemic cardiomyopathic
hearts.18,19 Although PDE5A and sGC enzyme activities were
not directly measured in the present study, the lower PKG
activity and cGMP concentration in HFPEF than in AS or
HFREF cannot be ascribed to higher expression of PDE5A
nor to lower expression of sGC or proBNP-108. They
therefore probably derived from lower myocardial NO bio-
availability because of higher nitrosative/oxidative stress,
which is known to directly impair NO-cGMP-PKG signal-
ing.16 In the present study, higher nitrosative/oxidative stress
was inferred from higher myocardial nitrotyrosine content in
HFPEF than in both HFREF and AS. The higher myocardial
Figure 4. A, Higher nitrotyrosylation of a
66-kDa protein in HFPEF than in HFREF
or AS, assessed by Western blot analysis
and normalized for actin. B, Representa-
tive immunohistochemical images stained
for nitrotyrosine in HFREF, HFPEF, and
AS. C, Higher myocardial nitrotyrosine
content assessed by quantitative immu-
nohistochemistry in HFPEF than in HFREF
or in AS. HFPEF indicates heart failure
with preserved ejection fraction; HFREF,
heart failure with reduced ejection frac-
tion; and AS, aortic stenosis.
Figure 5. Left, Myocardial proBNP-108 expression, assessed
by Western blot analysis and normalized for actin, is lower in
HFPEF than in HFREF and similar in HFPEF and AS. Right,
Representative Western blot lanes showing myocardial proBNP-
108 and actin expression. BNP indicates brain natriuretic pep-
tide, HFPEF, heart failure with preserved ejection fraction;
HFREF, heart failure with reduced ejection fraction; and AS, aor-
tic stenosis.
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nitrosative/oxidative stress observed in the HFPEF patients of
the present study could be related to the higher prevalence of
comorbidities associated with elevated oxidative stress, such
as obesity and DM (Table). Previous epidemiological studies
already reported HFPEF to be associated with obesity or
DM,20–22 both of which have also been implicated in diastolic
LV dysfunction.15,23–25
PKG Activity and Myocardial Diastolic
Dysfunction in HFPEF
Initial clinical studies on the myocardial contractile effects of
NO already observed NO to acutely improve LV relaxation and
diastolic stiffness.26 This beneficial action of NO on diastolic LV
function was explained by PKG-dependent phosphorylation of
troponin-I or titin and PKG-independent phosphorylation of
phospholamban. PKG-dependent phosphorylation of the giant
cardiomyocyte cytoskeletal protein titin is of special interest as
PKG-induced phosphorylation of its N2B segment lowers
Fpassive in human HF cardiomyocytes12 or in cardiomyopathic
myocardial strips.13 The present study establishes lack of
cardiomyocyte PKG activity as an important contributor to
myocardial diastolic dysfunction in HFPEF as it observed
lower myocardial PKG activity in HFPEF to correspond with
higher cardiomyocyte Fpassive and in vitro administration of
PKG to acutely lower the high Fpassive of HFPEF cardiomyo-
cytes. Apart from PKG-dependent control of diastolic LV
dysfunction in HFPEF, the present study also supports
involvement of nitrosative/oxidative stress. Such involvement
has also been suggested in recent experimental and clinical
studies. Oxidative stress leads to formation of disulfide
bridges within the titin molecule, which raises its overall
stiffness.27 In a mouse HFPEF model, oxidative stress uncou-
ples cardiac NOS and induces diastolic LV dysfunction.28
Finally, high plasma levels of methylated L-arginine metab-
olites were strongly related to diastolic LV dysfunction in
patients with HFREF.29 Accumulation in circulating blood of
methylated L-arginine metabolites mainly results from oxi-
dative stress inhibiting their breakdown by dimethylarginine
dimethylaminohydrolase.30
PKG Activity and Myocardial Remodeling
in HFPEF
In LV cardiomyocytes cultured from neonatal rat hearts, NO
or a cGMP analog attenuated the norepinephrine-induced
hypertrophic response through modulation of Ca2 influx.31
NO or a cGMP analog exerted these effects by raising PKG
activity, which suppressed prohypertrophic calcineurin-NFAT
signaling.32 These in vitro findings were in line with subsequent
in vivo experiments in mice subjected to TAC.8 In these mice,
sildenafil raised myocardial PKG activity and prevented or
reversed cardiomyocyte hypertrophy and interstitial fibrosis by
deactivating multiple prohypertrophic pathways.8 Furthermore,
in a transgenic mouse model, cardiomyocyte-specific PDE5
overexpression induced an exaggerated hypertrophic and
fibrotic response to LV pressure-overload, which was re-
versed by enhancing cGMP-PKG activity through suppressed
PDE5 gene expression.33 The ability of cGMP-PKG activity
to dampen maladaptive hypertrophy during LV pressure
overload was, however, seriously challenged by recent ex-
periments showing deletion of PKG to have no effect on
maladaptive myocardial hypertrophy in mice subjected to
TAC.34 The present study failed to observe relations between
myocardial PKG activity and cardiomyocyte diameter or
collagen volume fraction, when HFPEF patients were com-
pared with HFREF and AS. This failure could relate to
different prohypertrophic signaling pathways prevailing in
the different conditions35 and to more frequent use in the
present study of angiotensin converting enzyme inhibitors,
angiotensin II receptor blockers, and aldosterone receptor
antagonists in HF than in AS. The finding in AS of PKG
activity corresponding with Fpassive but not with cardiomyo-
cyte diameter suggests cardiomyocyte diastolic stiffness to
evolve independently from cardiomyocyte hypertrophy. This
concept also emerged from the VALIDD trial, in which only
3% of hypertensives had significant LV hypertrophy despite
all having diastolic LV dysfunction.36
Therapeutic Implications
Treatment of HFPEF remains uncertain as many large out-
come trials yielded neutral results. These neutral results were
variably explained by flawed trial design and testing of
treatment paradigms extrapolated from HFREF.3 By ob-
serving lower PKG activity and higher nitrotyrosine level
in HFPEF myocardium, the present study supports use in
HFPEF of NO-donors, PDE5 inhibitors, and drugs with
antioxidative properties such as statins. Acute administration
of NO donors is known to ameliorate diastolic LV function,26
whereas chronic use of isosorbide dinitrate combined with the
antioxidant hydralazine improved outcome in V-HeFT I and
A-HeFT trials.37,38 The clinical characteristics of the A-HeFT
HFREF patients revealed a high prevalence of obesity and
diabetes mellitus.39 HFPEF patients have a similar clinical
profile, and the present study provides direct evidence for
high myocardial oxidative stress in HFPEF. Combined use of
isosorbide dinitrate and the antioxidant hydralazine could
therefore be potentially favorable in HFPEF.
In HFREF, acute administration of sildenafil ameliorated
cardiac performance by lowering LV load,40 and in both
HFREF and HFPEF chronic administration ameliorated dia-
stolic LV dysfunction.10,11 The effect on diastolic LV dys-
function contributed, respectively, to improved clinical status
in HFREF and reduced pulmonary hypertension in HFPEF.
Acute administration of sildenafil was recently also reported
to lower diastolic LV stiffness and to increase myocardial
titin phosphorylation in an old hypertensive HFPEF dog
model,9 and chronic administration of sildenafil was previ-
ously demonstrated to improve TAC-induced concentric LV
remodeling in mice.8 Because of these encouraging clinical
and experimental results, sildenafil has been proposed as a
potential therapy for HFPEF.2,35 The present study, however,
suggests no superior effectiveness of sildenafil in HFPEF as
myocardial expression of PDE5A was similar in all patient
groups.
In the present study, myocardial proBNP-108 expression
was comparable between HFPEF and AS and higher in
HFREF than in both HFPEF and AS. These observations are
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consistent with proBNP-108 expression being regulated by
diastolic LV wall stress, which is higher in HFREF because
of eccentric LV remodeling and similar in HFPEF and AS
because of concentric LV remodeling.41 Because of compa-
rable proBNP-108 expression in HFPEF and AS, BNP is
unlikely to account for the widely different PKG activities
and cGMP concentrations observed in both conditions, which
were therefore attributed to higher nitrosative/oxidative stress
in HFPEF than in AS. Lower proBNP-108 expression in
HFPEF than in HFREF also explains the low positive
predictive value of BNP for the diagnosis of HFPEF.42 Acute
BNP administration was recently reported to lower diastolic
LV stiffness and to increase myocardial titin phosphorylation
in an old hypertensive HFPEF dog model9 but failed to
improve clinical end points in acutely decompensated HF
patients with LVEF 40%.43
Finally, the present study supports use of statins in HFPEF
because of their antioxidative properties. In experimental
hypertensive HF, statins were known to exert a variety of
favorable actions on concentric myocardial remodeling
such as regression of LV hypertrophy and prevention of
myocardial fibrosis.44 Moreover, usefulness of statins in
HFPEF was already demonstrated in a preliminary study
that showed statins to lower mortality with a relative risk
reduction of 22%.45
Limitations
The in vivo relevance of low myocardial PKG activity for
diastolic LV dysfunction in HFPEF is currently only sup-
ported by the lower diastolic LV stiffness observed in an old
hypertensive HFPEF dog model after administration of silde-
nafil or BNP and still needs to be clinically confirmed by
mechanistic studies and large outcome trials.
Myocardial ischemia was excluded only by absence of
significant (50%) epicardial coronary artery stenosis. In a
concentrically remodeled left ventricle, which was present in
both HFPEF and AS patients, absence of significant coronary
artery stenosis does not exclude subendocardial ischemia
at the site of biopsy procurement. Subendocardial ischemia
resulting from concentric LV remodeling is, however, an
unlikely cause for the higher Fpassive in HFPEF because AS
patients had a higher LV mass index/LV end-diastolic
volume index ratio but a lower Fpassive than HFPEF
patients.
Because of the higher prevalence of DM in the HFPEF
patients, higher Fpassive and lower myocardial PKG activity or
cGMP concentration could have resulted from DM-induced
upregulation of oxidative stress. In a subset analysis of
DM and DM patients, the findings in the DM patients,
however, resembled the overall results. This confirms the
higher Fpassive and lower PKG activity or cGMP concen-
tration in HFPEF to be associated with the HFPEF pheno-
type and not with a higher prevalence of DM in the HFPEF
group. Furthermore, the findings in the DM patients
also resembled the overall results apart from low PKG
activity in the AS-DM patients. The latter finding was,
however, consistent with a recent report on DM worsening
diastolic LV dysfunction and raising Fpassive in aortic
stenosis.15
Finally, immunohistochemical quantification of PKG ac-
tivity using pVASP phosphorylated at Ser239 lacks specificity
as Ser239 can also be phosphorylated by PKA. It therefore
only provides confirmatory evidence of the PKG enzyme
activity measurements performed on tissue homogenates.
Conclusions
HFPEF myocardium is characterized by downregulated NO-
cGMP-PKG signaling probably resulting from high nitrosa-
tive/oxidative stress. Low PKG activity raises cardiomyocyte
stiffness and is a potential target for a specific HFPEF
treatment strategy.
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CLINICAL PERSPECTIVE
Large trials testing modern heart failure pharmacotherapy in heart failure with preserved ejection fraction (HFPEF) had a neutral
outcome, probably because of failure to address features of myocardial dysfunction specific for heart failure with preserved
ejection fraction such as high-diastolic left ventricular stiffness. The latter results not only from myocardial fibrosis, but also from
high cardiomyocyte stiffness, which is linked to hypophosphorylation of the cytoskeletal protein titin and corrected by in vitro
administration of protein kinase G (PKG). In vivo administration of sildenafil, which raises myocardial PKG activity by
inhibiting breakdown of cyclic guanosine monophosphate, similarly improves diastolic left ventricular stiffness in a HFPEF dog
model and HFPEF patients with pulmonary hypertension. Because of these findings and the ongoing RELAX trial testing
sildenafil in HFPEF, the present study compared PKG activity, its downstream effects, and its upstream controls in left
ventricular endomyocardial biopsies of patients with HFPEF, HF with reduced ejection fraction, and aortic stenosis. Patients were
free of coronary artery disease, but more HFPEF patients were obese or had diabetes mellitus. The lowest myocardial PKG
activity was observed in HFPEF and associated with the highest cardiomyocyte stiffness, the lowest myocardial cyclic guanosine
monophosphate concentration, and the highest myocardial nitrosative/oxidative stress. The high prevalence among HFPEF
patients of metabolic disorders probably accounted for their high myocardial nitrosative/oxidative stress, which led to high
cardiomyocyte stiffness through a cascade of derangements consisting of low cyclic guanosine monophosphate concentration,
low PKG activity, and reduced phosphorylation of titin by PKG. Metabolic derangements therefore underlie diastolic left
ventricular dysfunction in HFPEF and should be targeted in future HFPEF treatment strategies.
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